Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-C5) - Biotin
| Code | Size | Price |
|---|
| LEI-LT7031-50ug | 50 ug | £377.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Virus
Antibody Isotype: Human IgG1
Antibody Clonality: Monoclonal
Antibody Clone: NP1-C5
Regulatory Status: RUO
Target Species:
- SARS-CoV-2
- Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Blue Ice
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
SARS-CoV-2 Nucleocapsid (N) Protein
Long Description:
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the Coronaviridae family, and its single-stranded, positive-sense RNA genome shares 79.6% identity with SARS-CoV1. The spike (S), envelope (E), membrane (M), and nucleocapsid proteins (N) are four essential structural proteins of SARS-CoV-22. The 46 kDa N protein is highly conserved and shares 90% homology with SARS-CoV3. Similar to SARS-CoV, SARS-CoV-2 has an N-terminal (NTD) and C-terminal domain (CTD), linked by a linker region. The NTD binds to RNA, while the CTD self-oligomerizes4,5, aiding viral genome packaging into a helical ribonucleoprotein complex6. The N protein also participates in viral transcription, replication, and modulation of cell signaling pathways7,8. Some vaccine and diagnostic assays9 have focused on the N protein as it is highly expressed during infection and activates antibodies3,10 and memory T cells11,12, found in convalescent sera. The N-protein also evades the innate immune system by inhibiting RNAi13, identifying it as a potential therapeutic target.
NCBI Gene:
43740575
Target:
SARS-CoV-2 Nucleocapsid (N)
References
1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020.
3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
Related Products
| Product Name | Product Code | Supplier | Anti-SARS-CoV-2 Spike RBD (Clone: 2165) | LEI-LT1900 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-SARS-CoV-2 Spike NTD (Clone 2146) | LEI-LT2000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2838) | LEI-LT3000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2381) | LEI-LT4000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2355) | LEI-LT5000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike NTD (Clone 2215) | LEI-LT6000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant SARS-CoV-2, Nucleocapsid (N) Protein | LEI-S854 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||